Publication date: Feb 01, 2025 Cancer-associated cachexia can inhibit immune checkpoint inhibitor (ICI) therapy efficacy. Cachexia’s effect on ICI therapy has not been studied in large cohorts of cancer patients ... Read more

Publication date: Jan 13, 2025 Concepts Keywords Dermatol Genomics Gpv Germline Immunotherapy Immunotherapy Inhibitor Melanoma Invest Semantics Type Source Name disease MESH Melanoma pathway KEGG Melanoma Original Article

Read more

Publication date: Jan 14, 2025 Concepts Keywords Clinical Bilateral Corneal Clinical Immunotherapy Corneal Melanoma Immunotherapy Ophthalmol Melanoma Metastatic Ophthalmol Perforation Secondary Semantics Type Source Name disease MESH melanoma pathway KEGG ... Read more

Publication date: Jan 15, 2025 H3 lysine 4 trimethylation (H3K4me3) modification and related regulators extensively regulate various crucial transcriptional courses in health and disease. However, the regulatory relationship between H3K4me3 ... Read more

Publication date: Jan 15, 2025 In clinical practice, thymopentin (TP-5) is a commonly utilized immunomodulatory peptide drug. The relatively short half-life of TP-5, however, significantly limits its applicability in immunotherapy. ... Read more

Publication date: Dec 01, 2025 Immune checkpoint blockade (ICB) has significantly improved the survival for many patients with advanced malignancy. However, fewer than 50% of patients benefit from ICB, highlighting ... Read more

Publication date: Jan 12, 2025 Neoadjuvant immunotherapy represents a pioneering approach in the preoperative treatment of cancer, offering novel avenues for tumor reduction and improved patient outcomes by modulating the ... Read more

Publication date: Jan 13, 2025 IO has transformed cancer management, but its adoption in advanced cancer patients varies by tumor type. With more Stage IV patients undergoing surgery, understanding site-specific ... Read more

Publication date: Jan 10, 2025 The development of mRNA vaccines represents a significant advancement in cancer treatment, with more than 120 clinical trials to date demonstrating their potential across various ... Read more

Publication date: Jan 10, 2025 Post-surgical tumor recurrence poses a major challenge in cancer treatment due to residual tumor cells and surgery-induced immunosuppression. Here, we developed hybrid nanoparticles, termed T-DCNPs, ... Read more